Signed in as:
filler@godaddy.com
Signed in as:
filler@godaddy.com
The Galleri blood test is an advanced multi-cancer early detection (MCED) test designed to identify over 50 types of cancer through a single blood draw. Developed using cutting-edge genomic and methylation technology, the test detects cancer-specific signals by analyzing cell-free DNA (cfDNA) shed by tumors into the bloodstream. It not only identifies the presence of cancer but also provides information about the likely tissue of origin, aiding in targeted follow-up diagnostics. While not a replacement for routine cancer screenings, the Galleri test offers a promising tool for detecting cancers that often go unnoticed until later stages, potentially improving early detection and survival outcomes.
A recent phase 2 clinical trial conducted by the University of Iowa has revealed that adding high-dose intravenous (IV) vitamin C to standard chemotherapy significantly improves outcomes for patients with stage 4 metastatic pancreatic cancer. The study found that patients receiving the combined treatment had an average overall survival of 16 months, compared to 8 months for those receiving chemotherapy alone. Additionally, progression-free survival increased from 4 to 6 months. Patients undergoing the combined therapy also reported fewer side effects and better tolerance to treatment. These promising results suggest that high-dose IV vitamin C could enhance the effectiveness of chemotherapy in treating this aggressive cancer. https://medicine.uiowa.edu/content/high-dose-iv-vitamin-c-plus-chemotherapy-doubles-survival-advanced-pancreatic-cancer
Give customers a reason to do business with you.
We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.